CTLA4 and cancer: Over the past 5 years, immunotherapy represented by immune checkpoint inhibitors (ICIs) targeting programmed death 1 (PD-1), programmed death ligand-1 (PD-L1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) has become an important milestone in cancer treatment5.